AHA Coding Clinic® for HCPCS - 2018 Quarter 4; For Your Information
Another HCPCS code for the reporting of biosimilar products
HCPCS code Q5108 , Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg, was recently added to the list of HCPCS codes utilized for the reporting of biosimilar products. This HCPCS code became effective for the reporting of services October 1, 2018. ...
Subscribe or sign in to view the full article.
Article Overview
This article is a short coding update focused on a newly added HCPCS item related to biosimilar product reporting. It is relevant to billing and coding staff who track quarterly code changes and effective dates for injectable drug reporting.
Why This Topic Matters
Staying current with HCPCS updates helps coding and billing teams recognize when new reporting options become available and avoid using outdated code lists.
What You Will Learn
- A short HCPCS update concerning biosimilar product reporting
- The general timing of when the update became effective
- Why monitoring code list changes matters for coding workflows
- How articles like this support billing and coding awareness for injectable products
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle teams
- Healthcare compliance staff
- Pharmacy billing professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com